lupus

three spotlights on a stage
Biotech

Merck KGaA sheds light on failed portion of phase 2 lupus trial

Merck KGaA has shed light on the failure in one lupus cohort, while pointing to secondary endpoint wins as proof that enpatoran still deserves a shot.
James Waldron Jun 12, 2025 9:41am
photo of the exterior of EMD Serono

After setback, Merck KGaA shows data justifying lupus ph. 3 push

May 21, 2025 9:50am
AI drug discovery pill machine learning drug targets data

Charles River and Valo pact nets preclinical lupus asset

Mar 26, 2025 6:30am
bumpy road rough bad path

Merck KGaA fails lupus trial arm, plans further development

Mar 6, 2025 7:25am
race car photo finish speed fast

Cabaletta's CAR-T shows 'robust benefit' in autoimmune patients

Feb 19, 2025 11:10am
Male and female superheroes posing in fluttering cloaks

Conduit taps Charles River to build AZ asset’s autoimmune cred

Feb 13, 2025 12:51pm